Angiogenesis is essential for growth and metastasis of solid tumors and probably also for hematological malignancies. Angiogenic inhibitors, like endostatin (ES) and PI-88, retard cancer growth. We tested these in mice with juvenile myelomonocytic leukemia (JMML), and in rats with acute myeloid leukemia (BNML). Eight weeks after transplantation and with a continuous drug treatment for the last 4 weeks, the leukemic cell mass decreased from almost 90% of all bone marrow cells to about 15 and 45% with ES, to about 35 and 55% with PI-88, and to about 10 and 25% with ES + PI-88 in the leukemic mice and rats, respectively. The numbers of normal human bone marrow cells transplanted into mice were unchanged by the treatments. The microvessel density in leukemic animals given ES or PI-88 was 10-50% of that in untreated animals. Notably, simultaneous treatment with ES and PI-88 led to a reduction of about 95% in JMML mice and 85% in BNML rats. In vitro proliferation of either JMML or BNML cells was not significantly altered by either drug, demonstrating the selectivity of ES and PI-88 as angiogenic inhibitors. In conclusion, anti-angiogenic therapy may be a valuable adjunct to conventional treatment of leukemia.
Introduction
It is well established that during tumor growth both the primary neoplastic and the subsequent metastasic growth are dependent on angiogenesis. [1] [2] [3] Recent data suggest that the development and progression of leukemias also require formation of new blood vessels. [4] [5] [6] Inhibition of the angiogenic process in bone marrow might therefore be a possible option in leukemic therapy. Endostatin, the C-terminal fragment of collagen XVIII, attenuated growth of several solid tumors in different experimental models by inhibiting angiogenesis. 7 An anticoagulant mannopentaose phosphate sulfate termed PI-88, was shown to inhibit angiogenesis in vitro as well as to reduce both growth and metastasis of an invasive rat mammary adenocarcinoma. 8 Whether endostatin and PI-88 may also hold promise for treating human leukemia has not been tested.
Juvenile myelomonocytic leukemia (JMML) is a rare hematological malignancy of early childhood. 9 Despite increasing knowledge about the pathophysiology of this disease, the therapeutic options remain scarce. Only bone marrow transplantation can offer a durable cure, however, with frequent relapses and severe side-effects. 9, 10 We have established a murine model of this disease by transplanting JMML cells into sublethally irradiated mice with severe combined immunodeficiency. 11 Acute myeloid leukemia in the adult human also carries a poor prognosis with reported 5-year survival usually less than 50%. 12 The transplantable promyelocytic leukemia in Brown Norway (BN) rats can serve as a model of human acute myeloid leukemia regarding growth pattern and response to treatment. 13, 14 We have used this BNML model extensively to study the bone marrow microenvironment during progression of the leukemic process. [15] [16] [17] Given these recent observations that angiogenesis might play a role in progression of leukemia, the aim of the present study was to examine if treatment with the anti-angiogenic compounds endostatin and/or PI-88 could arrest the expansion of malignant cell populations in our two experimental models of human myeloid leukemia, the JMML mice and the BNML rats.
Materials and methods

Study subjects and human donor samples
The protocol was approved by ethics committees. Bone marrow cells were collected from 10 children with untreated JMML and from three healthy children after informed, parental consent. Mononuclear cells were separated after erythrocyte aggregation and density gradient centrifugation (Lymphoprep, Nycomed, Oslo, Norway). Cells from the patients were further purified for JMML cells using monoclonal antibodies (mAbs) directed against the heterodimeric receptor complex for granulocyte-macrophage colony-stimulating factor (GM-CSF) expressed on these cells and magnetic sorting (MACS system; Miltenyi Biotec, Bergish Gladbach, Germany). 18 
Endostatin and PI-88
Recombinant human endostatin (Entre Med, Rockville, MD, USA) was expressed in the yeast Pichia pastoris (Invitrogen, San Diego, CA, USA), whereas PI-88 was obtained from Progen Industries (Brisbane, Australia).
8,19
Proliferation of bone marrow cells
Primary JMML cells were plated in methylcellulose (75 000 cells per dish), without cytokine supplements, for 2 weeks before enumeration of colony-forming units (Ͼ40 cells per clone). 18 Bone marrow cells from the healthy donors were grown and recorded in a similar manner, but with addition of stem cell factor (10 ng/ml) and granulocyte colony-stimulating factor (10 ng/ml). To some of these cultures we added either endostatin (10 g/ml) or PI-88 (10 g/ml). Bone marrow cells were harvested from the femoral bone of rats with leukemia, and the mononuclear cells were separated as described above before further purification of the leukemic (BNML) cells with the selective monoclonal anti-BNML antibody RM124 as described. 17, 20 To test the proliferative capacity of these BNML cells, they were grown in a humidified atmosphere (37°C, 5% CO 2 ) in liquid culture with supplemented (antibiotics and glutamine) RPMI 1640 medium and added tritiated thymidine (1 Ci/ml). After 24 h, the cells (50 000 per ml) were harvested and thoroughly washed three times before incorporation of the tritiated thymidine was measured with a ␤-counter.
Counting of microvessel density
To evaluate angiogenesis in the right femoral bone marrow of engrafted and control animals, the microvessel density was recorded using light microscopy and sections stained with a mAb raised against von Willebrand factor, a constituent of the endothelial lining of the microvasculature, as recently outlined. 5 
Experimental protocol
We used SCID/NOD mice to engraft JMML or normal bone marrow cells (10-20 million cells, i.v.) from individual donors, whereas splenic-derived BNML cells (15-20 million cells, i.v.) were transplanted into rats. 11, 15 Four weeks after transplantation some animals were killed with an overdose of barbiturate (i.p.), while others had an osmotic minipump (0.25 l/h; Alzet, Palo Alto, CA, USA) implanted (i.p.) after a laparatomy. The pumps were filled with either endostatin (delivering 0.5 mg/kg daily for 4 weeks), and/or PI-88 (delivering 20 mg/kg daily for 4 weeks). Bone marrow cells from the left femurs were then collected 8 weeks after the transplantation. Cells of human origin from the JMML transplanted mice were quantified with a human specific and fluorescent anti-CD45 mAb and a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA). 11 This method correlates well with both FISH stained sections and Southern blotting using human-specific probes, as previously shown. 11 We also used flow cytometry to determine the fraction of BNML cells with a secondary fluorescent antibody linked to the mAb RM124. 17, 20 This mAb specifically recognizes the BNML cells even at very low frequencies, such as those occurring in minimal residual disease. 20 The experiments were terminated with an overdose of barbiturate (i.p.).
Statistics
The measurements were performed in triplicate and the corresponding median value was used to calculate the means and s.e.m. for each experimental group of 10 animals. Differences were evaluated with Kruskal-Wallis test with the Bonferroni correction. A P value less than 0.05 was considered statistically significant.
Results
Synergistic effect of endostatin and PI-88 on inhibition of JMML growth
Four weeks after transplantation the JMML cells had reached a high level of engraftment (Figure 1a) . After an additional 4-week treatment with either endostatin or PI-88, a substantial
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Figure 1
Mice were transplanted with JMML cells (a) or normal human bone marrow cells (b, Control) and their femoral marrows analyzed after 4 weeks in untreated mice and after an additional 4 weeks in mice treated with endostatin (ES) and/or PI-88. Data are reported as means + s.e.m., n = 10 animals. *P Ͻ 0.05 and **P Ͻ 0.01 compared with untreated JMML-mice.
decrease in the malignant cell load in the bone marrow was apparent. Notably, when administered simultaneously, a marked synergistic effect of endostatin and PI-88 was noted. Bone marrow cells from healthy donors also engrafted to high levels, albeit lower than for the JMML cells (Figure 1b) . It was evident that neither endostatin nor PI-88 interfered with the engraftment of these normal cells. Figure 2a shows that engraftment of JMML cells was accompanied by an almost 10-fold increase in the microvessel density compared with control mice (Figure 2b) . A subsequent 4-week treatment with endostatin reduced the microvessel density to levels not different (P Ͻ 0.05) from those in untreated non-transplanted mice (Figure 2a vs b) . Also, PI-88 significantly attenuated microvascularization within bone marrows of mice engrafted with JMML. Importantly, a synergistic effect of a combined treatment with endostatin and PI-88 was evident. Neither endostatin nor PI-88 affected the microvessel density in mice engrafted with bone marrow from healthy donors (Figure 2b) . Interestingly, engraftment of bone marrow cells from healthy donors did not induce detectable angiogenesis, the microvessel density being similar to that in non-transplanted mice: 58 ± 6 vs 61 ± 8 vessels per 1.5 mm 2 (P Ͼ 0.05, n = 10). 
Endostatin and PI-88 reduced vascularization in the engrafted mouse bone marrow
Colony formation of JMML cells was not affected by endostatin or PI-88
Primary JMML cells seeded in semi-solid medium without growth factor supplements showed a marked, spontaneous colony formation (Figure 3a) , as previously noted. 18 While 1 g/ml of endostatin reportedly decreased DNA synthesis by endothelial cells, 21 addition of 10 g/ml endostatin had no apparent effect on the growth of the JMML cells, and neither did PI-88 interfere with the spontaneous JMML colony formation (Figure 3a) . To assess the responsiveness of the JMML cells, we added tumor necrosis factor ␣ (TNF␣; 10 ng/ml) to the cell cultures. While TNF␣ markedly enhanced JMML cell colony formation, a monoclonal anti-TNF␣ mAb (10 g/ml) given alone, attenuated it (Figure 3a) . Colony formation of bone marrow cells from healthy donors was unaffected by addition of endostatin, PI-88 or the anti-TNF␣ mAb (Figure 3b) . Addition of TNF␣ clearly decreased colony formation, thus demonstrating the known suppressive effect of this cytokine on normal hematopoiesis.
18,22
Combined treatment with endostatin and PI-88 reduced the malignant cell load and inhibited angiogenesis in the bone marrow of BNML rats
Both endostatin and PI-88 significantly decreased the content of leukemic cells in the BNML rats, the reduction being more marked with a combination of the two (Figure 4a) . Similarly, the bone marrow angiogenesis was also substantially impaired upon simultaneous administration of endostatin and PI-88 (Figure 4b ). In contrast, neither endostatin nor PI-88 nor both affected the microvessel density in non-transplanted control BN rats (Figure 4c ).
Endostatin and PI-88 did not affect proliferation of rat bone marrow cells
RM124-positive bone marrow cells were isolated from BNML rats and grown for 24 h in liquid culture. When incorporation of tritiated thymidine was used as a measure of the proliferative capacity of these leukemic cells, no effect was noted for either endostatin or PI-88 (Figure 5a) . Similarly, neither endostatin nor PI-88 affected proliferation of bone marrow cells harvested from non-transplanted control BN rats (Figure 5b) . To assess the responsiveness of bone marrow cells from BNML and control rats, we added the cytotoxic drug cyclophosphamide (30 mg/ml) to the liquid cell cultures. It is evident from Figure 5 that this drug profoundly inhibited proliferation of both leukemic and normal bone marrow cells, as expected.
23
Figure 4
Rats were transplanted with BNML cells (a) and their femoral bone marrows analyzed after 4 weeks in untreated rats and after an additional 4 weeks in mice treated with endostatin (ES) and/or PI-88. (b) The number of von Willebrand (vW) positive microvessels was counted with microscopy of femoral bone marrow sections after 4 weeks in untreated BNML rats and after an additional 4 weeks in BNML rats treated with endostatin (ES) and/or PI-88. (c) A similar microvessel count was performed in non-transplanted BN rats. Data are reported as means + s.e.m., n = 10 animals. *P Ͻ 0.05 and **P Ͻ 0.01 compared with untreated BNML rats.
Discussion
The major and novel finding of the present study was that a selective inhibition of angiogenesis in a non-solid neoplasia, such as leukemia, could markedly retard the malignant progression. Notably, while both endostatin and PI-88 alone substantially impaired the angiogenic process, a combined administration of the two proved to be the most effective. Importantly, the effect of single therapy with either endostatin or PI-88, and the synergism obtained with simultaneous treatment, were consistently observed in two different rodent models of human myeloid leukemia.
The JMML has been extensively studied, mainly because of its aggressiveness and poor response to conventional antileukemic therapy. A major feature of JMML is its autonomous growth pattern, which is most likely the result of endogenous
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Figure 5
(a) Samples of BNML cells from 10 leukemic rats were grown with or without endostatin (ES) or PI-88 or cyclophosphamide (Cyclo) in liquid culture and given tritiated thymidine. (b) Similarly, we cultured samples of bone marrow cells from 10 non-transplanted BN rats. Data are reported as means + s.e.m. *P Ͻ 0.05 compared with untreated rats.
production of cytokines such as TNF␣ and GM-CSF. 18, 22 The ability to study this disease in vivo with immunodeficient mice transplanted with primary JMML cells offers a unique possibility to examine the effects of various anti-leukemic regimens prior to initiation of phase I trials. 11 Similarly, the BNML rat model for human acute myeloid leukemia has given valuable insight into the mechanism of leukemogenesis as well as the pharmacodynamics of various cytotoxic drugs frequently used in the treatment of this disease. 13, 14, 23 Hence, the JMML mice and the BNML rats provided us with valuable tools to study the effects of inhibiting angiogenesis in models mimicking human leukemia.
Recently, it was reported that chemotherapy of acute leukemia led to a reduced number of microvessels within the bone marrow. 24 However, whether a selective targetting of neovascularization within the bone marrow may impair the leukemic process has not been fully clarified. Endostatin has proved to be a powerful inhibitor of angiogenesis in various solid tumors. 7 Progression of a liver tumor and increase of its microvessel density were associated with a decreased expression of endostatin precursor molecules. 25 Increased tit-Leukemia ers of anti-endostatin antibodies were detected in connection with expansion of a brain tumor. 26 These observations emphasize the pivotal role of endostatin in the regulation of cancer-related microvascular formation. How endostatin inhibits the formation of new vessels, is as yet unclear. Previous studies have suggested that it can decrease both proliferation and migration as well as induce apoptosis of endothelial cells in tumors. 7, 21 Furthermore, Kim et al 27 showed recently that endostatin could inhibit endothelial and tumor cell invasion by blocking a matrix metalloproteinase.
Although less extensively studied, the phosphomannopentaose sulphate PI-88 consistently reduced angiogenesis in both in vitro and in vivo models. 8 Possibly, PI-88 exerts its antiangiogenic effects by interfering with heparan sulphate, a molecule known to harbor angiogenic growth factors such as basic fibroblast growth factor and vascular endothelial growth factor (VEGF). 8 Irrespective of the exact molecular mechanisms, endostatin and PI-88 most likely act, at least partly, on different angiogenic pathways since (1) synergistic effects were observed, and (2) putatively, PI-88 acts as a heparan sulphate decoy or inhibitor of heparanase, 8 whereas endostatin reportedly does not require heparin binding to inhibit VEGFinduced endothelial cell migration. 28 Albeit it was outside the scope of the present study, further studies into the mechanisms of action of these two anti-angiogenic compounds are warranted.
The present data show that both endostatin and PI-88 effectively and selectively inhibit formation of microvessels within the bone marrow of leukemic mice and rats, since neither compound affected the growth of JMML, BNML or normal bone marrow cells. Whether these agents may affect leukemic cells in other hematopoietic tissues such as spleen and liver was not tested. Another important observation was that engraftment of normal human bone marrow cells did not lead to angiogenesis in the recipient mouse bone marrow, and that treatment with endostatin and PI-88 did not affect the density of bone marrow microvessels in these mice. Possibly, the formation of new blood vessels is regulated differently in normal and neoplastic tissues, for example via a different expression pattern of vascular growth factors or their receptors. 29 In this respect, TNF␣ is a possible mediator since this cytokine stimulates JMML cell growth both in vitro and in vivo, 11, 18, 22 as well as being an inducer of angiogenesis. 29 Non-transplanted mice and rats treated with endostatin and/or PI-88 did not loose weight, and the blood concentration of hemoglobin, leukocytes and platelets remained within normal limits (data not shown). Moreover, treatment with either endostatin or PI-88 did not affect proliferation of normal bone marrow cells (present study). Furthermore, the normal wound healing process following a skin lesion was not detectably affected in endostatin-treated animals, 30 or PI-88 treated animals (Podger, personal communication). Collectively, these independent data indicate that neither compound conveys any apparent toxicity.
The present study supports the notion that angiogenesis may be required for leukemic growth. We also provide evidence that leukemic regression can be selectively and efficiently induced in two rodent models of human myeloid leukemia. Therefore, anti-angiogenic therapy might be a valuable adjunct to cytotoxic therapy or possibly part of pre-transplantation conditioning regimens. Further studies are warranted to verify the role of angiogenesis in human leukemia.
